Form 4: Viridian Therapeutics COO Thomas Beetham Reports Stock Purchase

Thomas Beetham, Chief Operating Officer of Viridian Therapeutics, reports the acquisition of 5,000 shares of common stock at $23.41 per share.

Summary

• On September 27, 2024, Thomas Beetham, the Chief Operating Officer of Viridian Therapeutics, acquired 5,000 shares of common stock at a price of $23.41 per share.
• Following this transaction, Beetham directly owns 6,000 shares of Viridian Therapeutics.
• The report also includes shares acquired under the company's 2016 Employee Stock Purchase Plan (ESPP) on September 19, 2024.
• A Power of Attorney was executed on September 30, 2024, granting Stephen Mahoney, Seth Harmon, and Jennifer Tousignant the authority to execute Forms 3, 4, and 5 on Beetham's behalf.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the insider buying activity, which suggests confidence in the company's future. However, it's a single transaction and doesn't provide a comprehensive view.

Positives

• The purchase of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It's a common practice for executives to purchase shares in their own companies.

Stakeholder Impact

• The stock purchase by the COO could positively influence shareholder sentiment.

Key Dates